Evidence map›Paper›PMID 41938080›Full record

ArticleJTO clinical and research reports2026

Clinical Concordance of Pan Lung Cancer PCR Panel Covering 167 Actionable Variants Across 11 Genes and Other Validated Assays in the LC-SCRUM-Asia Registry.

Shingo Matsumoto, Takashi Seto, Christer Svedman, Terufumi Kato, Kazumi Nishino, Naoki Furuya, Yuichiro Ohe, Ryo Toyozawa, Masahiro Kodani, Masato Shingyoji and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shingo MatsumotoDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Takashi SetoPrecision Medicine Asia, Tokyo, Japan.
Christer SvedmanPrecision Medicine Asia, Tokyo, Japan.
Terufumi KatoDepartment of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Kazumi NishinoDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Naoki FuruyaDivision of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Yuichiro OheDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Ryo ToyozawaDepartment of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Masahiro KodaniDivision of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Masato ShingyojiDivision of Respirology, Chiba Cancer Center, Chiba, Japan.
Yuji ShibataDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kaname NosakiDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Hiroki IzumiDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Yoshitaka ZenkeDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Yuri MurataDepartment for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Japan.
Kiyotaka YohDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Koichi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The increasing number of actionable alterations across multiple genes in NSCLC has led to the need for molecular testing. Next-generation sequencing is one solution, but the turnaround time and cost limit its use. We assessed the concordance of a Pan Lung Cancer PCR Panel covering 167 variants across 11 genes in NSCLC with validated assays. Methods: A total of 568 NSCLC samples (168 with Results: The success rate for the polymerase chain reaction (PCR) panel was 100%. The overall percent agreement for the panel results for all genes was higher than 98.5%: Conclusions: The Pan Lung Cancer PCR Panel was highly concordant with other assays. The panel can be performed in local laboratories with a rapid turnaround time and represents an attractive alternative to next-generation sequencing for patients with lung cancer.

Indexed as

molecular testingnext-generation sequencingNSCLCPCR

Identifiers

PMID41938080
PMCPMC13050060

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.